Literature DB >> 8958957

Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice.

M F Neurath1, I Fuss, B Kelsall, K H Meyer zum Büschenfelde, W Strober.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8958957     DOI： 10.1111/j.1749-6632.1996.tb52695.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  7 in total

Review 1.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

2.  Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40.

Authors:  Xiaochang Xue; Ting Feng; Suxia Yao; Kyle J Wolf; Chang-Gong Liu; Xiuping Liu; Charles O Elson; Yingzi Cong
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

Review 3.  Mucosal T lymphocytes--peacekeepers and warriors.

Authors:  Hilde Cheroutre; Mitchell Kronenberg
Journal:  Springer Semin Immunopathol       Date:  2005-06-02

4.  The role of nuclear factor-kappa B in bacterial translocation in cholestatic rats.

Authors:  D Weber-Mzell; P Zaupa; T Petnehazy; H Kobayashi; G Schimpl; G Feierl; P Kotanko; M Höllwarth
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

5.  Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease.

Authors:  D Berrebi; M Besnard; G Fromont-Hankard; R Paris; J F Mougenot; P De Lagausie; D Emilie; J P Cezard; J Navarro; M Peuchmaur
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 6.  Act Locally, Act Globally-Microbiota, Barriers, and Cytokines in Atherosclerosis.

Authors:  Natalia Kurilenko; Aliia R Fatkhullina; Aleksandra Mazitova; Ekaterina K Koltsova
Journal:  Cells       Date:  2021-02-07       Impact factor: 6.600

7.  Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.

Authors:  Claudia Pena Rossi; Stephen B Hanauer; Ratko Tomasevic; John O Hunter; Ira Shafran; Hans Graffner
Journal:  BMC Gastroenterol       Date:  2009-03-20       Impact factor: 3.067
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.